Update on tolterodine extended-release for treatment of overactive bladder

about

Anticholinergic use in children: Persistence and patterns of therapy.

P2860

Q36823081-BDC6FC59-45C3-4473-AF9F-C37CE833D038

P2860

Update on tolterodine extended-release for treatment of overactive bladder

Item

http://www.wikidata.org/entity/Q37283585

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Update on tolterodine extended-release for treatment of overactive bladder

@en

Update on tolterodine extended-release for treatment of overactive bladder.

@nl

type

Item

label

Update on tolterodine extended-release for treatment of overactive bladder

@en

Update on tolterodine extended-release for treatment of overactive bladder.

@nl

prefLabel

Update on tolterodine extended-release for treatment of overactive bladder

@en

Update on tolterodine extended-release for treatment of overactive bladder.

@nl

P1476

Update on tolterodine extended-release for treatment of overactive bladder

@en

P2093

Chi Chiung Grace Chen

http://www.w3.org/2001/XMLSchema#string

Tola Omotosho

http://www.w3.org/2001/XMLSchema#string

P2860

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

Which anticholinergic drug for overactive bladder symptoms in adults

Discontinuation Rates of Anticholinergic Medications Used for the Treatment of Lower Urinary Tract Symptoms

Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Antimuscarinics for treatment of overactive bladder.

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity.

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.

P304

185-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OAJU.S7232

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258337424

http://www.w3.org/2001/XMLSchema#string

P698

24198627

http://www.w3.org/2001/XMLSchema#string

P932

3818890

http://www.w3.org/2001/XMLSchema#string

Update on tolterodine extended-release for treatment of overactive bladder

about

P2860

P2860

Update on tolterodine extended-release for treatment of overactive bladder

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932